GLP-1s are driving returns on R&D investments for Big Pharma, report says

Știință și Tehnologie

In This Story NVO -2.58% LLY -1.87% PFE -2.35% AMGN -3.23% Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s ( NVO -2.58% ) popular diabetes drug Ozempic. Suggested Reading Market rally runs out of steam amid economic anxieties Officials think you should delete your 23andMe data. Here's how The Trump administration is being asked to relax some AI chip rules Waymo is sending its robotaxis to Washington, D.C. Here's what to know CC

din zilele anterioare